171261
Dorsomorphin
≥95% (HPLC), liquid, AMPK inhibitor, Calbiochem
Sinónimos:
InSolution AMPK Inhibitor, Compound C, Dorsomorphin, AMPK Inhibitor I, BMP Inhibitor I
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Acerca de este artículo
Fórmula empírica (notación de Hill):
C24H25N5O
Número CAS:
Peso molecular:
399.49
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleServicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
AMPK Inhibitor, Compound C, InSolution, ≥95%, 10 mM, AMPK Inhibitor
SMILES string
[n]21ncc(c2ncc(c1)c4ccc(cc4)OCCN5CCCCC5)c3ccncc3
InChI
1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2
InChI key
XHBVYDAKJHETMP-UHFFFAOYSA-N
assay
≥95% (HPLC)
form
liquid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated (hygroscopic)
protect from light
shipped in
wet ice
storage temp.
2-8°C
Quality Level
Categorías relacionadas
Biochem/physiol Actions
Cell permeable: yes
EC100 = 2.5 µM against BMP pathway-dependent dorsoventral development; EC50 = 5 µM against VEGF signaling-dependent intersomitic vessel formation in zebrafish embryo in vivo
Primary Target
AMPK
AMPK
Product competes with ATP.
Reversible: yes
Target IC50: 25.1, 148, and 234.6 nM, against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity, respectively
Disclaimer
Toxicity: Irritant (B)
Other Notes
Hao, J., et al. 2010. ACS Chem.Biol.5, 245.
Kim, E.K., et al. 2004. J. Biol. Chem.279, 19970.
Lee, M., et al. 2003. J. Biol. Chem.278, 39653.
Inoki, K., et al. 2003. Cell115, 577.
Fryer, L.G., 2002. FEBS Lett.531, 189.
Zhou, G., et al. 2001. J. Clin. Invest.108, 1167.
Kim, E.K., et al. 2004. J. Biol. Chem.279, 19970.
Lee, M., et al. 2003. J. Biol. Chem.278, 39653.
Inoki, K., et al. 2003. Cell115, 577.
Fryer, L.G., 2002. FEBS Lett.531, 189.
Zhou, G., et al. 2001. J. Clin. Invest.108, 1167.
Packaging
Packaged under inert gas
Physical form
Supplied as a 10 mM (1 mg/250 µl) solution of AMPK Inhibitor, Compound C (Cat. No. 171260) in DMSO.
Preparation Note
Following initial use, aliquot and freeze (-20°C). Once opened, stock solutions are stable for up to 3 months at -20°C.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
General description
A cell-permeable pyrrazolopyrimidine compound that inhibits against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity (IC50 = 25.1, 148, and 234.6 nM, respectively), while exhibiting much reduced or little effect toward ALK5/TGFβR-I, ZAPK, Syk, PKCθ, PKA, or JAK3. Shown to block both BMP pathway-dependent dorsoventral development (EC100 = 2.5 µM) and VEGF signaling-dependent intersomitic vessel formation (EC50 = 5 µM) in zebrafish embryo in vivo. Commonly used in combination with AMPK activators AICAR (Cat. No. 123040 ) and/or Metformin (Cat. No. 317240 ) for studying AMPK-dependent cellular events in vitro and physiological responses in animals in vivo.
Clase de almacenamiento
10 - Combustible liquids
wgk
WGK 2
flash_point_f
188.6 °F - closed cup - (Dimethylsulfoxide)
flash_point_c
87 °C - closed cup - (Dimethylsulfoxide)
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Reetta A E Eriksson et al.
Frontiers in medicine, 9, 1052318-1052318 (2022-12-31)
Gene therapy would greatly benefit from a method to regulate therapeutic gene expression temporally. Riboswitches are small RNA elements that have been studied for their potential use in turning transgene expression on or off by ligand binding. We compared several
Ernesto Pena Calderin et al.
Molecular metabolism, 66, 101637-101637 (2022-11-19)
Physical activity has been shown to reduce the risk of CVD mortality in large-cohort longitudinal studies; however, the mechanisms underpinning the beneficial effects of exercise remain incompletely understood. Emerging data suggest that the risk reducing effect of exercise extends beyond
Karina Krotova et al.
Human gene therapy, 31(19-20), 1124-1131 (2020-06-05)
Adeno-associated virus (AAV)-based gene therapy is undergoing major expansion into clinical practice, with two treatments currently being granted Food and Drug Administration (FDA) approval. However, the presence of pre-existing neutralizing antibodies (NAB) is one of the significant hurdles for the
David P Santos et al.
Methods in molecular biology (Clifton, N.J.), 1538, 53-66 (2016-12-13)
Human embryonic stem cells (ESCs) are characterized by their unique ability to self-renew indefinitely, as well as to differentiate into any cell type of the human body. Induced pluripotent stem cells (iPSCs) share these salient characteristics with ESCs and can
Xiaochen Yu et al.
Frontiers in physiology, 13, 817542-817542 (2022-03-19)
Increases in glucose production and decreases in hepatic glycogen storage induce glucose metabolic abnormalities in type 2 diabetes (T2DM). Empagliflozin, a sodium-dependent glucose transporter 2 (SGLT2) inhibitor, is an effective hypoglycemic drug; however, the effects of empagliflozin on hepatic gluconeogenesis
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico